Compare PDFS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | CAPR |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2000 | 2011 |
| Metric | PDFS | CAPR |
|---|---|---|
| Price | $33.53 | $28.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $33.00 | ★ $41.38 |
| AVG Volume (30 Days) | 302.4K | ★ 1.0M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,270,465.00 |
| Revenue This Year | $21.58 | N/A |
| Revenue Next Year | $18.61 | $17,308.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.91 | $4.30 |
| 52 Week High | $36.99 | $40.37 |
| Indicator | PDFS | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 60.32 |
| Support Level | $26.91 | $22.09 |
| Resistance Level | $35.13 | $30.71 |
| Average True Range (ATR) | 1.71 | 1.67 |
| MACD | 0.25 | 0.42 |
| Stochastic Oscillator | 88.39 | 80.07 |
PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.